DOR BioPharma, Inc.
RiVax maker provides business and clinical update; RiVax phase I trial complete
Published in FDA Law Weekly, November 17th, 2005
DOR announced that the investigational new drug application (IND) for its orBec program had been transferred from the U.S. Food & Drug Administration's (FDA) gastrointestinal products division to the oncology drug products division. From its inception till the present time, the orBec IND has been held and guided by the gastrointestinal division.
DOR has been and will continue to be in contact with the oncology division in the coming weeks to review the orBec program and plan for the new drug application (NDA) filing. In its initial correspondence with DOR about the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
Source: FDA Law Weekly (2005-11-17)
More Articles from FDA Law Weekly
- Barrier Therapeutics, Inc.
U.S. FDA submission for Zimycan deemed a complete response - Baxter Healthcare Corp.
U.S. FDA approves Flexbumin, an albumin solution, in a flexible container - Becton, Dickinson and Company
U.S. FDA grants 510(k) clearance for urine preservative transport - BioMarin Pharmaceutical, Inc.
U.S. FDA accepts Orapred ODT NDA filing - Biopure Corp.
U.S. FDA maintains clinical hold on IND application for RESUS phase II/III trial of Hemopure - Bioterrorism
Medical professionals leave Guantanamo with new impressions - More from this issue of FDA Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
